BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12526918)

  • 1. Expression of sorcin predicts poor outcome in acute myeloid leukemia.
    Tan Y; Li G; Zhao C; Wang J; Zhao H; Xue Y; Han M; Yang C
    Leuk Res; 2003 Feb; 27(2):125-31. PubMed ID: 12526918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and clinical implication of soluble resistance-associated calcium-binding protein gene and multi-drug resistance gene in leukemia.
    Li G; Tan Y; Yang C; Zhao C; Zhao H; Wang J; Xue Y; Han M; Qian L; Zhao C
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):370-4. PubMed ID: 12408767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
    Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
    Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and clinical implications of the soluble drug resistance-related calcium-binding protein (sorcin) gene in leukemia patients.
    Li G; Tan Y; Yang C; Zhao C; Zhao H; Wang J; Xue Y; Han M; Qian L; Zhao C
    Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):293-6. PubMed ID: 12411058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells.
    Zhou Y; Xu Y; Tan Y; Qi J; Xiao Y; Yang C; Zhu Z; Xiong D
    Leuk Res; 2006 Apr; 30(4):469-76. PubMed ID: 16213583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia].
    Do JH; Oh SH; Song EJ; Chung JS; Kang CD; Lee EY
    Korean J Lab Med; 2007 Aug; 27(4):229-36. PubMed ID: 18094581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
    Leith CP; Chen IM; Kopecky KJ; Appelbaum FR; Head DR; Godwin JE; Weick JK; Willman CL
    Blood; 1995 Sep; 86(6):2329-42. PubMed ID: 7545025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells.
    Kawakami M; Nakamura T; Okamura N; Komoto C; Markova S; Kobayashi H; Hashimoto N; Okumura K; Sakaeda T
    Biol Pharm Bull; 2007 Jun; 30(6):1065-73. PubMed ID: 17541155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of tetrandrine on SORCIN gene expression in K562/A02 cell line].
    Li J; Chen BA; Zhu MS; Gao F; Ding JH; Gao C; Sun YY; Cheng J; Wang J; Zhao G; Song HH; Ma Y; Bao W; Sun XC; Cheng HY; Xu WL; Shen HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):65-9. PubMed ID: 18315902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins.
    Hu Y; Cheng X; Li S; Zhou Y; Wang J; Cheng T; Yang M; Xiong D
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):789-98. PubMed ID: 24013575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.
    Zhou DC; Zittoun R; Marie JP
    Leukemia; 1995 Oct; 9(10):1661-6. PubMed ID: 7564506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
    Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
    Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
    Ho MM; Hogge DE; Ling V
    Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
    Advani AS; Shadman M; Ali-Osman F; Barker A; Rybicki L; Kalaycio M; Sekeres MA; de Castro CM; Diehl LF; Moore JO; Beaven A; Copelan E; Sobecks R; Talea P; Rizzieri DA
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):473-6. PubMed ID: 21156465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
    Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
    Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
    van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
    Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.
    Del Poeta G; Stasi R; Aronica G; Venditti A; Cox MC; Bruno A; Buccisano F; Masi M; Tribalto M; Amadori S; Papa G
    Blood; 1996 Mar; 87(5):1997-2004. PubMed ID: 8634450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.